Driving research of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS),
Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia and Long Covid

Et fjerde ME / CFS Collaborative Research Center

SISTE NYTT

Vi er glade for å kunngjøre at vi har lagt til et fjerde ME / CFS Collaborative Research Center (CRC) for å bli med i vårt Prosjekt for å få en slutt på ME / CFS.

Dette vil bli ledet av Alain Moreau, PhD, ME / CFS Collaborative Research Center ved CHU Sainte-Justine/Université de Montréal i Québec, Canada og vil tjene til å øke vår internasjonale samarbeidsinnsats.

Dr. Moreau og laboratoriet hans har forsket på ME / CFS i flere år. Etter å ha møtt Ronald W. Davis, PhD, direktør for OMFs vitenskapelige nemnd, og OMFs CEO, Linda Tannenbaum i 2017, har Dr. Moreau vært en del av ME-/CFS-arbeidsgruppen og har flere ganger gjort presentasjoner på en vitenskapelig konferanse som blir holdt ved Stanford University. I tillegg arrangerte han den første ME / CFS Canadian Collaborative Conference som ble holdt i Montreal i mai 2018.

«Jeg bestemte meg først for å invitere Dr. Moreau til å delta i ME / CFS-arbeidsgruppen fordi han har vist at han har flere nye tilnærminger for å forstå sykdommen. Arbeidet hans vil komplettere arbeidet til andre forskere. CRC i Montreal utvider vårt internasjonale samarbeid for å løse ME / CFS.» Ronald W. Davis, PhD

Om forskningen

Det nye ME / CFS Collaborative Research Center ved Université de Montréal ser etter årsaken til sykdommen med fokus på gjennomførbare terapeutiske mål. Deres innovative forskningsprogram ligger på grensen til genetisk disponering og eksterne faktorer som kan ha endret genuttrykket hos ME / CFS-pasienter (epigenetiske endringer).

De håper at overvåking av forskjellige biomarkørendringer under en stresstest vil bidra til å belyse patofysiologien til ME / CFS og bidra til å identifisere spesifikke molekylære signaturer. Samtidig har de tenkt å utvikle bedre kliniske verktøy slik at klinikere kan diagnostisere ME / CFS og velge de beste behandlingene for å imøtekomme deres medisinske behov. Til slutt håper de å finne en kur for å få en slutt på ME / CFS.

 

Dr. Moreaus forskerteam ved ME / CFS Collaborative Research Center
CHU Sainte-Justine/Université de Montréal i Québec, Canada

Lær mer om ME / CFS Collaborative Research Center, Université de Montréal

Om Dr. Moreau

Alain Moreau, PhD, er professor i Institutt for stomatologi, Fakultet for odontologi og Institutt for biokjemi og molekylær medisin, Det medisinske fakultet, ved Université de Montréal, Montréal, Québec, Canada. I tillegg er Dr. Moreau direktør for Network for Canadian Oral Health Research. Han er vitenskapelig leder for Viscogliosi Laboratory in Molecular Genetics of Musculoskeletal Diseases, Sainte-Justine University Research Center, Montréal, Québec.

Dr. Moreaus hovedinteresser ved studien er pediatrisk skoliose, osteoartritt, osteoporose og myalgisk encefalomyelitt. Dr. Moreau er medlem av Open Medicine Foundation Scientific Advisory Board og er direktør for Interdisciplinary Canadian Collaborative Myalgic Encephalomyelitis Research Network, et nasjonalt forskningsnettverk finansiert av Canadian Institute of Health Research.

______________________________________________________________

Vi er så stolte av de skarpe hjernene fra hele verden som har blitt med Prosjektet for å få en slutt på ME / CFS. Dr. Moreaus kolleger kommer fra Canada, Frankrike, Iran, Moldova, Kina, Egypt, Columbia, Spania, Russland og Romania!

STØTT ARBEIDET TIL VÅRT
INTERNASJONALE TEAM AV FORSKERE

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

What are the advantages of giving from your Donor Advised Fund (DAF)?

  • Your gifts to your donor advised fund entitle you to an immediate income tax deduction at the time of contribution.
  • You avoid capital gains tax on appreciated assets you place in your donor advised fund.
  • Your fund’s investment gains accumulate tax free.
  • Funds are distributed to Open Medicine Foundation in your name and immediately put to use to support our worldwide research efforts.

How do I make a donation through my DAF?

Just click on the DAF widget below. It is simple and convenient to find your fund among the over 900 funds in our system.

Still can’t find your fund? 

  • Request a grant distribution through your Donor Advised Fund sponsor
  • Be sure to use OMF’s EIN #26-4712664
  • You can also designate OMF as a beneficiary for your Donor Advised Fund
  • Questions? Give us a call at 650-242-8669 

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

Averting a second pandemic:

Open Medicine Foundation leads groundbreaking international study of

Long COVID’s conversion to ME/CFS

AGOURA HILLS, CALIF.  — Open Medicine Foundation (OMF) is leading a large-scale international collaborative study investigating the potential conversion of Post-Acute Sequelae SARS-CoV-2 infection — more commonly known as Long COVID or Post-COVID Syndrome —  to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a chronic, life-altering disease with no known cause, diagnostic test or FDA approved treatments available.

Up to 2.5 million people in the U.S. alone suffer from ME/CFS; the COVID-19 pandemic could at least double that number. An estimated 35 percent of Americans who had COVID-19 have failed to fully recover several months after infection, prompting many to call it “a potential second pandemic.”

OMF recognized a familiar health crisis emerging, one with eerie similarities to ME/CFS. This crisis presented a unique opportunity to understand how a viral infection — in this case COVID-19 — may develop into ME/CFS in some patients. The goal is to find targeted treatments for ME/CFS patients and ultimately prevent its onset in people infected with SARS-CoV-2 or other infections.

The federal government is only now investing in Post-COVID research, with no focus on its connection to ME/CFS. OMF has already engaged researchers for the largest-scale study of its kind, solely supported by private donors who have contributed over one million dollars to date. When fully funded, the five million dollar, three-year study will be conducted across the globe at OMF funded Collaborative Research Centers, led by some of the world’s top researchers and ME/CFS experts.

BACKGROUND

In a significant percentage of patients, infections preceded their development of ME/CFS.  For example, according to the CDC about one in ten infected with Epstein-Barr virus, Ross River virus, or Coxiella burnetti develop symptoms that meet the criteria for ME/CFS.

THE STUDY

The ability to follow the development of ME/CFS from a known viral infection is unprecedented to date and crucial to researchers’ understanding of the disease. The focus of this study is to find the biological differences between persons returning to good health after COVID-19 and persons who remained ill more than six months after infection and developed ME/CFS.  Understanding these alterations in key pathways can lead to groundbreaking discoveries including new biomarkers, drug targets, and prevention and treatment strategies.

###

About Open Medicine Foundation

Established in 2012, Open Medicine Foundation leads the largest, concerted worldwide nonprofit effort to diagnose, treat, and prevent ME/CFS and related chronic, complex diseases such as Post Treatment Lyme Disease Syndrome, Fibromyalgia, and Post COVID. OMF adds urgency to the search for answers by driving transformational philanthropy into global research. We have raised over $28 Million from private donors and facilitated and funded the establishment of six prestigious ME/CFS Collaborative Research Centers around the world. To learn more, visit www.omf.ngo.

CONTACT:

Heather Ah San

Development and Communications Manager

1-650-242-8669

heather@omf.ngo